



About the recommendation of the GINA strategy report on asthma step 1

Serena Ferretti , Mariannita Gelsomino and Stefano Miceli Sopo

Affiliation: Dept of Woman and Child Health, Policlinico Gemelli University Foundation IRCCS, Catholic University of Sacred Heart, Rome, Italy.

Correspondence: Serena Ferretti, Università Cattolica del Sacro Cuore, Largo A. Gemelli, 8, 00168, Rome, Italy.
E-mail: serena.ferretti01@icatt.it

 @ERSpublications

There is not yet sufficient evidence to transfer the use of as-needed low dose ICS–formoterol, as GINA has recommended since 2019, instead of as-needed SABA to patients affected by step 1 asthma
<https://bit.ly/2G1IieN>

Cite this article as: Ferretti S, Gelsomino M, Miceli Sopo S. About the recommendation of the GINA strategy report on asthma step 1. *Eur Respir J* 2021; 57: 2003324 [<https://doi.org/10.1183/13993003.03324-2020>].

This single-page version can be shared freely online.

To the Editor:

“GINA 2019: a fundamental change in asthma management.” This is how REDDEL *et al.* [1] headline their editorial on the report in question. REDDEL *et al.* [1] express a fundamental concept: “GINA no longer recommends treatment of asthma in adolescents and adults with SABA alone. Instead, to reduce their risk of serious exacerbations, all adults and adolescents with asthma should receive either symptom-driven (in mild asthma) or daily inhaled corticosteroid (ICS)-containing treatment.” We have some doubts about the full suitability of this change.